Tuesday 9th April, 2013
10:00am to 11:30am
Overview: New Legislation & Guidance for Pharmacovigilance will apply in the European Union (EU) beginning July 2012. To assist in its implementation with sponsors, applicants and license holders, a series of Guidance Documents is being written, which will replace the current set of Volume 9A of the Rules Governing Medicinal Products in the EU. The legal framework for pharmacovigilance on Medicinal Products for Human Use has now been updated, through an amended EU Regulation (No 1235/2010) and Directive (2010/84/EC).
Why should you attend: This webinar is focused on understanding the new requirements for Good Pharmacovigilance Practices that will begin to become effective in the European Union beginning July 2012. The New Guidance on Good Pharmacovigilance Practices (GVP) has been updated by Module, of which the first seven Modules have been disclosed for public consultation. This Course will describe the Regulatory Updates, Guidance Updates and thoughts on how some Member States’ Competent Authorities will proceed with implementation.
These regulatory changes will also impact the EU Clinical Trial Directive and expectations of sponsors in the protection of patients and public health, before, during and after a clinical study.
Learning Objectives: Upon completion of this course, attendees will have a thorough knowledge of the updated framework surrounding Good Pharamcovigilance Practices (GVP). This will include updates to the EU regulation, Directive and the first seven PV Modules, which have been published for consultation. The content of this course is designed to simplify the understanding of the new requirements and to provide attendees with the latest information on what the European Commission believes is a significant area of improvement in the region.
Areas Covered in the Session:
Overview of EU Regulatory structure
EU Pharmacovigilance : Why make changes now?
New definitions for the updated directive and regulation
Organization of PV Modules
Update to the EU Pharmacovigilance legislation
How the new legislation will better protect patient safety
How the new legislation will affect Marketing Authorization Holders
How the new legislation will affect Sponsors of Clinical Studies
Adverse Drug Reaction Reporting
Periodic Safety Update Reports
Post-Authorization Safety Studies
Changes to labeling
The Pharmacovigilance Risk Assessment Committee
Implementation timing & expectations
Who Will Benefit: This course will be beneficial to:
Clinical Trial Heads
CRAs and CRCs
QA / Compliance personnel
Clinical Research Scientists
QA / QC Auditors and Staff
For the past 9 years, Bob has been President of RJR Consulting, Inc. The company assists the pharmaceutical, medical device and biotech industries in understanding and complying with International Regulations affecting compliance, new product development, manufacturing and quality assurance.
Livermore Common, Fremont, CA, 94539
Sign in to add slides, notes or videos to this session
9th April 2013